Dipeptidyl‐Peptidase 4 Inhibition and the Vascular Effects of Glucagon‐like Peptide‐1 and Brain Natriuretic Peptide in the Human Forearm

Author:

Devin Jessica K.1,Pretorius Mias2,Nian Hui3,Yu Chang3,Billings Frederic T.2,Brown Nancy J.1

Affiliation:

1. Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

2. Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN

3. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN

Abstract

Background Dipeptidyl‐peptidase 4 ( DPP 4) inhibitors improve glycemic control in patients with diabetes mellitus by preventing the degradation of glucagon‐like peptide‐1 ( GLP ‐1). GLP ‐1 causes vasodilation in animal models but also increases sympathetic activity; the effect of GLP ‐1 in the human vasculature and how it is altered by DPP 4 inhibition is not known. DPP 4 also degrades the vasodilator brain natriuretic peptide ( BNP ) to a less potent metabolite. This study tested the hypothesis that DPP 4 inhibition potentiates the vasodilator responses to GLP ‐1 and BNP in the human forearm. Method and Results Seventeen healthy subjects participated in this randomized, double‐blinded, placebo‐controlled crossover study. On each study day, subjects received DPP 4 inhibitor (sitagliptin 200 mg by mouth) or placebo. Sitagliptin increased forearm blood flow and decreased forearm vascular resistance without affecting mean arterial pressure and pulse. GLP ‐1 and BNP were infused in incremental doses via brachial artery. Venous GLP ‐1 concentrations were significantly higher during sitagliptin use, yet there was no effect of GLP ‐1 on forearm blood flow in the presence or absence of sitagliptin. BNP caused dose‐dependent vasodilation; however, sitagliptin did not affect this response. GLP ‐1 and BNP had no effect on net norepinephrine release. Conclusions These data suggest that GLP ‐1 does not act as a direct vasodilator in humans and does not contribute to sympathetic activation. Sitagliptin does not regulate vascular function in healthy humans by affecting the degradation of GLP ‐1 and BNP . Clinical Trial Registration URL : www.clinicaltrials.gov/ Unique identifier: NCT 01413542.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3